TBH I don't know which of those gets me more excited....they all have such huge potential. Mind boggling, really. I guess this really demonstrates the benefits of a "Platform Technology", compared to a single cure for a single condition (which is the norm for listed companies).
So they have 4 in the pipeline in the near-medium term. Rohan H reckons each of them have potential earnings of over $1 Billion. (That's with a "B".) Let's be super-ultra conservative and imagine that each treatment "only" earns half of that. That's a $2 billion income spread over 3 billion shares. So 67cps. The usual PER for biotech companies is about 18. Let's be conservative and say "10". So $0.67 x 10 = AD$6.70.
I'm not sure if PYC can take 4 treatments all the way through Phase 3, even if the first one for RP11 was a huge success. Would the others be licensed out? Or would we be taken over long before then? (And, if so, as what price?)
Have a great weekend, FHC
PYC Price at posting:
7.1¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)